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488Objectives:We previously reported that patients with preoperative B-type natriuretic peptide levels of 30 pg/mL
or more have increased risk of postoperative atrial fibrillation after pulmonary resection. This study evaluated
the effects of human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmo-
nary resection for lung cancer.
Methods: Aprospective, randomized studywas conductedwith 40 patients who had preoperative elevated B-type
natriuretic peptide (30 pg/mL) and underwent a scheduled pulmonary resection for lung cancer. Results were
compared between patients who received low-dose human atrial natriuretic peptide and those who received a pla-
cebo.Theprimary endpointwas the incidenceof postoperative atrial fibrillation during thefirst 4 days after surgery.
Results: The incidence of postoperative atrial fibrillation was significantly lower in the human atrial natriuretic
peptide group than in the placebo group (10% vs 60%; P<.001). Patients in the human atrial natriuretic peptide
group also showed significantly lower white blood cell counts and C-reactive protein levels after surgery.
Conclusions: Continuous infusion of low-dose human atrial natriuretic peptide during lung cancer surgery had
a prophylactic effect against postoperative atrial fibrillation after pulmonary resection in patients with preoper-
ative elevation of B-type natriuretic peptide levels. A larger sample size is needed to establish the safety and
efficacy of this intervention. (J Thorac Cardiovasc Surg 2012;143:488-94)Atrial fibrillation (AF) is the most common type of cardiac
arrhythmia encounteredduring the early postoperative period
after a pulmonary resection procedure.1,2 Although transient
in most cases, AF sometimes results in a serious outcome,
including thromboembolic events and hemodynamic
deterioration, which finally leads to increased mortality.3,4
Human atrial natriuretic peptide (hANP) consists of 28
amino acids and has shown a variety of biologic effects
when used as treatment for heart failure in Japan. It is
now known that hANP exhibits a wide range of cardiopro-
tective effects, including antifibrosis, antihypertrophy, anti-
inflammation, and inhibition of sympathetic nerve activity,
the renin–angiotensin–aldosterone system, and endothelin
synthesis.5,6 Beneficial effects of hANP on postoperative
left ventricular remodeling have been reported in patients
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The Journal of Thoracic and Cardiovascular Surghemodynamic, structural, and electrophysiologic changes
in the atria.9 Because hANP exerts beneficial effects on he-
modynamics10 and atrial electrical remodeling,11 it is plau-
sible to expect some protective effects of hANP against
postoperative AF, and our retrospective analysis showed
that the treatment with hANP was associated with the re-
duction of postoperative AF (unpublished data).
We previously reported that patients with lung cancer
who have a preoperative plasma B-type natriuretic peptide
(BNP) level of 30 pg/mL or more have increased risk of de-
velopment of postoperative AF.12 The purpose of this study
was to examine prospectively the effects of hANP on post-
operative AF in such high-risk patients undergoing pulmo-
nary resection for lung cancer.MATERIALS AND METHODS
Patients
This study was conducted at National Toneyama Hospital in Japan. All
patients who underwent an elective pulmonary resection procedure for
non–small cell lung cancer were evaluated for potential enrollment. Inclu-
sion criterion was a preoperative BNP level of 30 pg/mL or more. The cut-
off value of BNP (30 pg/mL) was selected on the basis of our previous
results,12 which showed that this cutoff value of preoperative BNP can pre-
dict the incidence of postoperative AF with high sensitivity and specificity
among patients undergoing pulmonary resection for lung cancer. Exclusion
criteria for this analysis were previous AF, antiarrhythmic drug use,
dysthyroidism, renal failure requiring hemodialysis, repeated pulmonary
resection, benign tumor, and recent (<1 month) angina pectoris or myocar-
dial infarction. Patients were not excluded if they were taking b-blockers
for reasons other than cardiac arrhythmia.ery c February 2012
Abbreviations and Acronyms
AF ¼ atrial fibrillation
BNP ¼ B-type natriuretic peptide
CRP ¼ C-reactive protein
hANP ¼ human atrial natriuretic peptide
WBC ¼ white blood cell
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This was a prospective, double-blind, randomized, placebo-controlled,
parallel-groups study. A description of patients screened, consenting, ran-
domly assigned, and enrolled in the study is shown in Figure 1. Patients
were randomly allocated to receive hANP or placebo. The specific random-
ization sequence was computer generated. In the hANP group, the subjects
received hANP (0.025 mg/kg/min without a bolus dose; Daiichisankyo
Pharmaceutical Inc, Tokyo, Japan), whereas those in the placebo group re-
ceived a 5% glucose physiologic solution for 3 days. Each treatment was
started after the pulmonary artery and vein had been divided. All patients
received preoperative epidural anesthesia for painmanagement, which usu-
ally remained in place for 2 to 4 days or until the chest drainage tubes were
removed, after which patients were switched to oral analgesia. Other post-
operative management methods included early ambulation and low-flow
nasal oxygen supplementation, as necessary. The study protocol was ap-
proved by the institutional review board of National Toneyama Hospital,
and all patients provided written informed consent before participation
(trial registration number JPRN-UMIN 000001524).
Measurements
The levels of BNP were determined before surgery. The levels of atrial
natriuretic peptide and C-reactive protein (CRP), as well as white blood cell
(WBC) counts, were determined before surgery and on postsurgical days 1,FIGURE 1. Summary of patients screened, giving consent, randomly alloc
The Journal of Thoracic and Ca3, and 7, and again 1 month after surgery. The plasma concentrations of
atrial natriuretic peptide and BNP were determined with an immunoradio-
metric assay (Shionoria ANP; Shionogi Pharmaceutical, Osaka, Japan) and
a chemiluminescence enzyme immunoassay (MI02 Shionogi BNP; Shio-
nogi Pharmaceutical), respectively. Intravenous fluid was administered at
a constant rate (80 mL/h) through a peripheral venous catheter or a central
venous catheter before oral intake was resumed. Hemodynamic parameters
such as systolic blood pressure, diastolic blood pressure, heart rate, and uri-
nary volume were recorded before surgery and for the first 4 days after sur-
gery. Transthoracic echocardiography was performed before surgery, as
previously described elsewhere.13
Postoperative AF
The primary end point of the studywas the incidence of postoperativeAF
during the first 4 days after surgery. The peak incidence of AF has been re-
ported to occur on the second postoperative day, with most events seen dur-
ing the first 4 postoperative days.14Any episode ofAF thatwas registered by
the continuousmonitoring systemwithin the first 4 days on a rhythm strip or
the 12-lead electrocardiogram that lasted for longer than 5 minutes, with or
without symptoms, was defined as postoperative AF.14
Adverse Events
In this study, adverse events other than AF were monitored for 30 days
after surgery. These were defined as death, congestive heart failure, myo-
cardial infarction, angina pectoris, pneumonia, acute respiratory failure,
pulmonary embolism, and hypotension.
Sample Size
Sample size calculations for the primary end point were conducted on the
basis of a retrospective analysis of our institutional database, which revealed
an incidence of postoperativeAFof 68% among patientswith a preoperative
BNP level of 30 pg/mL or more, whereas the incidence of postoperative AF
was only 17% among patients with a preoperative BNP level of 30 pg/mL or
morewhowere treated with hANP.We calculated the sample sizewith a sta-
tistical power of 80% (b ¼ .8) and a significance level of 5% (a ¼ .05),ated, and included in the study. hANP, Human atrial natriuretic peptide.
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considering a dropout rate of 20%, we enrolled 20 patients for each arm.
Statistical Analysis
Data are expressed as the mean SD or as the median with interquartile
range. Comparisons among all repeated parameters were analyzed by
repeated-measures analysis of variance. Comparisons between the 2 groups
were assessed by Student t test for normally distributed variables, by the
Mann-Whitney U test for nonnormally distributed variables, and by c2
test for categoric variables. All data were analyzed with the SPSS statistical
software package (version 11.0; IBM Corporation, Armonk, NY).TABLE 1. Patient characteristics and preoperative cardiopulmonary func
Variables
Age (y, mean  SD)
Male (no.)




Ischemic heart disease (no.)
Medication (no.)
b–Blockers
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Statins






Complete video-assisted thoracoscopic surgical procedure (no.)
Operating time (min, mean  SD)
Blood loss (mL, mean  SD)
Mediastinal lymph node dissection (no.)
Use of catecholamines (no.)




Vital capacity(% predicted, mean  SD)
FEV1 (% predicted, mean  SD)
FEV1/FVC (%, mean  SD)
Diffusing capacity of the lung for carbon monoxide(% predicted, mean  SD)
PaO2 (mm Hg, mean  SD)
PaCO2 (mm Hg, mean  SD)
LV end-diastolic diameter (mm, mean  SD)
LV end-systolic diameter (mm, mean  SD)
LV ejection fraction (%)
LV mass index (g/m2, mean  SD)
Left atrial diameter (mm, mean  SD)
Systolic pulmonary arterial pressure (mm Hg, mean  SD)
e0 (cm/s, mean  SD)
E/e0 (mean  SD)
Atrial natriuretic peptide (pg/mL, mean  SD)
B-type natriuretic peptide(pg/mL, median and interquartile range)
hANP, Human atrial natriuretic peptide; FEV1, Forced expiratory ventilation in 1 second; F
diastolic velocity; E/e0, early transmitral velocity/tissue Doppler mitral annular early dias
490 The Journal of Thoracic and Cardiovascular SurgRESULTS
Study Population
Between April 2008 and April 2009, a total of 44 patients
were enrolled in the study (Figure 1). Ultimately, 20 pa-
tients were randomly assigned to each arm and analyzed.
There were no significant differences between the 2 groups
with regard to baseline characteristics, surgical data, preop-
erative cardiopulmonary function, and serum levels of atrial




(n ¼ 20) P value
73  7 70  8 .39
10 (50%) 13 (65%) .17
22.4  2.5 22.2  3.0 .43
9 (45%) 11 (55%) .54
8 (40%) 5 (25%) .32
2 (10%) 2 (10%) .99
2 (10%) 2 (10%) .99
1 (5%) 1 (5%) .99
2 (10%) 3 (15%) .64
3 (15%) 2 (10%) .64
68.2  15 69.9  19 .78
1 (5%) 2 (10%) .56
1 (5%) 1 (5%) .99
17 (85%) 17 (85%) .99
1 (5%) 0 (0%) .32
12 (60%) 11 (55%) .49
234  75 242  80 .38
157  58 139  99 .41
17 (85%) 15 (75%) .19
1 (5%) 3 (15%) .30
16 (80%) 14 (70%) .48
3 (15%) 3 (15%) .99
1 (5%) 3 (15%) .30
98.0%  21% 103%  19% .28
85.2%  13% 87.9%  21% .36
74.9%  6.8% 75.2%  9.4% .47
94.7%  19% 90.6%  22% .28
85.1  13 90.4  14 .66
41.9  2.6 39.6  3.5 .38
41.8  3.9 41.9  5.0 .56
26.8  2.4 27.1  3.9 .21
66.3  3.8 65.5  4.3 .24
122  30 107  61 .35
35.3  3.9 36.1  7.4 .36
34.4  4.8 34.1  2.8 .87
7.41  2.4 7.28  1.1 .52
9.82  3.1 9.50  2.5 .16
25.7  11 28.2  18 .41
48.5 (32–62) 41.8 (34–82) .65
VC, forced vital capacity; LV, left ventricular; e0, tissue Doppler mitral annular early
tolic velocity.
ery c February 2012
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ejection fraction in both groups was similar and greater
than 60%. Both groups had relatively high preoperative
BNP levels, and lobectomies were performed in most cases.Incidence of Postoperative AF
Postoperative AF was identified in 12 subjects in the pla-
cebo group and 2 in the hANP group during the first 4 days
after surgery. The incidence of postoperative AF was signif-
icantly lower in the hANP group (10% vs 60%; P<.001).
The total group peak incidence of AF was on the first 2 post-
operative days (86%), with all events occurring on the first
postoperative day in the hANP group (Figure 2). Most of the
patients in whom AF developed received b-blockers or the
combination of digoxin and verapamil on the onset day. All
the patients with postoperative AF had restoration of sinus
rhythm within 2 weeks.Adverse Events
There were no postoperative deaths, thromboembolic
events, or incidents of congestive heart failure associated
with AF in either group. There were no subjects with an ad-
verse event in the hANP group and only 1 subject with an
adverse event in the placebo group. That patient had acute
respiratory distress syndrome develop but recovered after
a few days.Hemodynamics
There were no statistical differences between the groups
with regard to systolic blood pressure, diastolic blood pres-
sure, heart rate, and urinary volume (Figure 3, A). None of
the subjects received a blood transfusion. There were also
no statistical differences in the dosage of catecholamines
between the groups. None of the subjects had the hANP in-
fusion discontinued as a result of hypotension. In our anal-
ysis of urinary volume, a second peak was recognized on
day 2 after surgery in the placebo group, the so-called ‘‘re-
filling phenomenon,’’ whereas such a peak was not ob-
served in the hANP group.FIGURE 2. Daily distribution of postoperative atrial fibrillation in the
placebo and human atrial natriuretic peptide (hANP) groups. D, Postoper-
ative day.
The Journal of Thoracic and CaPostoperative Levels of Atrial Natriuretic Peptide
The hANP group showed significantly higher levels of
atrial natriuretic peptide than did the placebo group on
days 1 and 3 after surgery. These levels decreased after
the discontinuation of treatment (Figure 3, B).Postoperative WBC Counts and CRP Levels
The hANPgroup showed significantly lowerWBC counts
and CRP levels than did the placebo group on postsurgical
days 3 and 7 and 1 month after surgery (Figure 3, C).P
MDISCUSSION
These results are the first to show that continuous infu-
sion of low-dose hANP has a prophylactic effect against
postoperative AF in patients at risk for development of
AF who undergo pulmonary resection for lung cancer.
The infusion of low-dose hANP did not significantly change
postoperative hemodynamics; however, it did decrease the
postoperative WBC counts and CRP levels. These findings
suggest attenuation of inflammatory changes associated
with the prevention of postoperative AF. We also found
that continuous infusion of low-dose hANP was well toler-
ated, with no clinically significant adverse effects, including
hypotension, being observed. Our findings indicate that
low-dose hANP is a viable treatment option to prevent post-
operative AF in high-risk patients undergoing noncardiac
thoracic surgery.
Cardinale and colleagues14 and our group12 have re-
ported that elevated preoperative levels of N-terminal
proBNP fragment or BNP serve as remarkably accurate pre-
dictors of incidence of AF among patients undergoing non-
cardiac thoracic surgery. On the basis of our previous
study,12 we used 30 pg/mL of plasma BNP as a cutoff value
for the inclusion criteria of high-risk patients. This figure is
probably justified, as indicated by the finding that the sub-
jects in the placebo group had AF develop at a high fre-
quency (60%) after surgery.
Administration of hANP is considered to have various ef-
fects on postoperative AF in patients undergoing pulmonary
resection. First, it produces vasodilatory and natriuretic ef-
fects, leading to the reduction of cardiac overload. Several
studies have shown that infusion of hANP increases stroke
volume index and decreases pulmonary capillary wedge
pressure, while at the same time also improving hemody-
namics and clinical status in patients with congestive heart
failure.10,15 Sezai and coworkers,7 however, recently re-
ported that low-dose hANP infusion (0.02 mg/kg/min) did
not significantly change hemodynamics, although it did re-
duce the postoperative peak level of creatine kinase isoen-
zyme MB and improve postoperative left ventricular
function after coronary artery bypass grafting. Consistent
with those results, we found no statistical differences
between the hANP and placebo groups with regard tordiovascular Surgery c Volume 143, Number 2 491
FIGURE 3. Changes from preoperative baseline (Preop.) in perioperative parameters by postoperative day (D) and at 1 postoperative month (M). Each
point with bars shows the mean  SD. A, Changes in perioperative systolic blood pressure, diastolic blood pressure, heart rate, and urinary volume. There
were no statistical differences between the placebo and human atrial natriuretic peptide (hANP) groups. B, Changes in plasma concentrations of atrial na-
triuretic peptide (ANP) in patients undergoing elective pulmonary resection for lung cancer who received an infusion of human atrial natriuretic peptide
(hANP) or a placebo for 3 days. Double asterisk indicates P<.001. C, Changes in white blood cell counts (WBC) and C-reactive protein levels (CRP)
in patients undergoing elective pulmonary resection for lung cancer who received an infusion of human atrial natriuretic peptide (hANP) or a placebo
for 3 days. Asterisk indicates P<.05; double asterisk indicates P<.001.
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Mpostoperative hemodynamics. In the placebo group, a sec-
ond peak of urinary volumewas observed on day 2 after sur-
gery, whereas this refilling phenomenon was not observed
in the hANP group. These results suggest that infusion of
low-dose hANP does not significantly change hemodynam-
ics, although it does prevent the refilling phenomenon,
which could lead to a reduction in acute volume overload,
resulting in prevention of postoperative AF.
Administration of hANP also inhibits inflammatory
reactions. AF is often caused by structural and electrophys-
iologic changes in the atria that are induced by inflamma-
tion.16 Epidemiologic and clinical studies have shown an
association between CRP and AF.17 Chen and colleagues18
also reported that inflammatory cell infiltration was in-
creased in the atrial myocardium of patients with AF,
whereas Ishii and associates19 found increased neutrophil
cell infiltration in the atrial wall in a canine pericardiotomy
and lateral right atriotomy model. In addition, the degree of
atrial inflammation in the latter study was associated with
proportional increases in the inhomogeneity of atrial
conduction after cardiac surgery, as well as increases in
the incidence and duration of AF. Moreover, anti-
inflammatory therapy with methylprednisolone signifi-
cantly decreased the inhomogeneity of atrial conduction
after the atriotomy and shortened the duration of AF. Yosh-
ida and coworkers11 reported that exogenous atrial natri-
uretic peptide prevented atrial electrical remodeling in
a canine rapid atrial stimulation model and speculated
that this effect might have been the result of direct action
on the atrial myocardium. In this study, patients in the
hANP group showed significantly lower WBC counts and
CRP levels after surgery than did those in the placebo
group. Previous studies have also reported that hANP in-
hibited sympathetic nerve activity and oxidative stress.15
The administration of hANP might prevent atrial electrical
remodeling through the attenuation of inflammatory
changes, oxidative stress, and sympathetic nerve activation,
resulting in prevention of postoperative AF.
Finally, it is important to note that the hANP group had
significantly lower WBC counts and CRP levels than did
the placebo group at 1 month after surgery, even though
the period of hANP infusion lasted only 3 days. We believe
that it is important to observe and report long-term progno-
ses in a larger population in future studies.
Study Limitations
This was a single-site clinical study, and thus the number
and characteristics of the patients enrolled were restricted.
A multicenter study with a larger sample size is necessary
to validate and generalize the findings reported here and
the safety of this intervention. Furthermore, echocardio-
graphic and cardiac catheter examinations were not per-
formed after surgery in this study, and there are no data
regarding possible beneficial effects on left ventricularThe Journal of Thoracic and Cafunction or invasive hemodynamic parameters during the
early period after surgery. In addition, the use of catechol-
amines is not common among patients undergoing pulmo-
nary resection with preserved left ventricular function;
however 3 patients in the placebo group and 1 patient in
the hANP group did receive catecholamines, which may
have caused the incidents of AF.CONCLUSIONS
This study is the first to show that continuous infusion of
low-dose hANP during lung cancer surgery can exert a pro-
phylactic effect against postoperative AF after pulmonary
resection without major adverse events in patients with pre-
operative elevation of BNP levels. Additional studies with
larger sample sizes are warranted to determine whether
these effects can be observed in other patients and translated
into improved clinical outcomes.
We acknowledge statistical advice from Yuko Ohno, PhD.References
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